Radioirnmunodetection of cervical carcinoma xenografts with 111 In-labeled MAb Cx-99 detected by a hand-held gamma detector

Purpose: To establish a radioimmunodetection (RAID) system for localization of cervical cancer by labeling 111-indium ((111)In) to a monoclonal antibody against cytokeratin 19 (MAb Cx-99), and detecting it with a hand-held gamma detector in an animal model.

Methods: MAb Cx-99 was labeled with 111-Indium by the DTPA chelating method. From the second day to the seventh day after injection of this immunoconjugate into athymic nude mice bearing cervical cancer cell line CC7T xenografts, the biodistribution ratios of tumor and non-tumor radioactivity were detected by a hand-held gamma detector. Data were also correlated with the data detected by the conventional gamma counter.

Results: The labeling efficiency of this (111)In-labeled MAb Cx-99 and (111)In-labeled MOPC was 91.6% and 95.5%, respectively. After injection, the liver, kidney and lung were initially noticed to have high radioactivity, but the localization of tumor/tissue ratios increased progressively as time passed, indicating the effect of delayed detection for distinguishing tumor from non-tumor tissues. Except for the spleen, the range of tumor/tissue ratios was 1.18-32.7 and 1.14-39.35 for the fourth day and the seventh day, respectively. The tumor/spleen ratio remained low until the seventh day after injection, thus indicating that the spleen might have a different excretion rate.

Conclusion: This study indicated the feasibility of a hand-held detection system in the localization of cervical cancer after injection of (111)In-labeled MAb Cx-99. The effect of delayed detection was obvious by the decreasing high bindings in the liver, spleen and kidney, with the applicable detection time being four to seven days after injection.

Radioimmunodetection, Monoclonal antibody, Cytokeratin 19, Hand-held gamma detector, Cervical cancer

[1] Miller A. B., Nazeer S., Fonn S., Brandup-Lukanow A., Rehman R., Cronje H., Sankaranarayanan R., et al.: "Report on consensus conference on cervical cancer screening and management". Int. J. Cancer., 2000, 86, 440.

[2] Kim S. H., Choi B. I.,L eeH . P.,K ang S. B., Choi Y.M .,H anM . C., Kim C. W.: "Uterine cervical carcinoma: comparison of CT and MR findings". Radiology, 1990, 175, 45.

[3] Kim S. H., Kim S. C., Choi B. I.,H an M. C.: "Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging". Radiology, 1994, 190, 807.

[4] Yu K. K,,H ricak H., Subak L. L., Zaloudek C. J., Powell C. B.: "Preoperative staging of cervical carcinoma: phased array coil fast spin-echo versus body coil spin-echo T2 weighted MR imaging". Am. J. Roentgenol., 1998, 171, 707.

[5] Heller P. B.,M alfetanoJ .H .,B undy B. N.,e t al.: "Clinical-pathologic study of stage Ilb, III and IVa carcinoma of the cervix: extended diagnostic evaluation for para-aortic node metastasis - a Gynecological Oncology Group study". Gynecol. Oncol., 1990, 38, 425.

[6] Goldenberg D. M., Larson S. M.: "Radioimmunodetection in cancer identification". J. Nucl. Med., 1992, 33, 803.

[7] Surwit E. A., Childers J.M., Krag D. M., et al.: "Clinical assessment of "'In-CYT-103 immunoscintigraphy in ovarian cancer". Gynecol. Oncol., 1993, 48, 285.

[8] Powell M. C., Perkins A. C., Pimm M. V.,J etaily M. A.,W astie M. L., Durrant L., Baldwin R. W., Symonds E. M.: "Diagnostic imaging of gynecologic tumors with the monoclonal antibody 791T/36". Am. J. Obstet. Gynecol., 1987, 157, 28.

[9] Baum R. P.: "Immunoscintigraphy follow-up of cancer patients". In: Surgical Gynecologic Oncology. Burghardt E., Coed Webb M. J.,M onaghan J.M., Kindermann G. (eds). N.Y.: Thieme Medical Publishers, 1993, 249.

[10] Juang C.M .,W ang P.H.,Y enM . S.,L ai C. R.,N gH . T.,Y uan C. C. "Application of tumor markers, CEA, T PA, and SCC-Ag in patients with low-risk FIGO stage 1B and IIA squamous cell carcinoma of uterine cervix". Gynecol. Oneal., 2000, 76, 103.

[11] Bonfrer J.M., Gaarenstroom K. N., Korse C. M., Van Bunningen B. N., Kenemans P.: "Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen". Anticancer Res., 1997, 17, 2329.

[12] Yuan C. C., Tsai L. C.,H su S. C., Ng H. T., Tsia S. J., Chen H. M.et al.: "Production and characterization of a monoclonal antibody (Cx-99) against cervical carcinoma". Br. J. Cancer., 1992, 65, 201.

[13] Yuan C. C.,H uang T. S., Ng H. T., Liu R. S.,H ungM . W., Tsai L. C.: "Elevated cytokeratin-19 expression associated with apoptosis resistance and malignant progression of human cervical carcinoma". Apoptosis, 1998, 3, 161.

[14] Yuan C. C., Tsai L. C., Lee T. W., Ng H. T., Yeh S. H.: "Radioimmunodetection of human cervical carcinoma xenograft by "'Inlabeled monoclonal antibody MAb Cx-99". Int. J. Gynecol. Obstet., 1995, 49, S33.

[15] Sakahara H., Endo K., Nakashima T., Koizumi M., Kunimatsu M., Kawamura Y. et al.: "Localization of human osteogenic sarcoma xenografts in nude mice by a monoclonal antibody labeled with radioiodine and indium-Il l". J. Nucl. Med., 1987, 28, 342.

[16] Avital S.,H addad R., Troitsa A., Kashtan H., Brazovsky E., Gitstein G. el al.: "Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation". Cancer, 2000, 89, 1692.

[17] de Labriolle-Vaylet C., Cattan P., Sarfati E., Wioland M., Billotey C., Brocheriou C. et al.: "Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery". Clin. Cancer Res., 2000, 6, 363.

[18] Adams S., Baum R. P.,H ertel A.,W enisch H.J.,S taib-Sebler E., Herrmann G. et al.: "Intraoperative gamma probe detection of neuroendocrine tumors". J. Nucl. Med., 1998, 39, 1155.

[19] Ko J. L., Chang C.M .,C hao K. C.,W u K. D.,N g F. T.,H u C. P.: "Establishment and characterization of human cervical carcinoma cells in continuous culture". Chin. J. Microbial. lmmunol., 1980, 13, 273.

[20] Goldenberg D. M.: "Monoclonal antibodies in cancer detection and therapy". Am. J. Med., 1993, 94, 297.

[21] Van Trappen P. 0., Gyselman V. G., Lowe D. G., Ryan A., Oram D. H., Bosze P. et al.: "Molecular quantification and mapping of lymph-node micrometastases in cervical cancer". Lancet, 2001, 357, 15.

[22] Banal A.,H acene K., Berthelot-Ruff E.,M ahe E., Fontana X., Pichon M. F.: "Comparison of Cyfra 21-1 and SCC assays in head and neck tumours". Tumour Biol., 2001, 22, 27.

[23] Stieber P., Zimmermann A., Reinmiedl J.,M uller C.,H offmann H., Dienemann H.: "CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC)". Anticancer Res., 1999, 19, 2665.

[24] Beatty J. D., Duda R. B.,W illiams L. E.,S heibani K., Paxton R. J., Beatty B. G. et al.: "Preoperative imaging of colorectal carcinoma with "'In-labeled anticarcinoembryonic antigen monoclonal antibody". Cancer Res., 1986, 46, 6494.

[25] Collier B. D., Abdel-Nabi H., Doerr R. J. et al.: "Immunoscintigraphy performed with "'In-labeled CYT-103 in the management of colorectal cancer: Comparison with CT". Radiology, 1992, 185, 179.

[26] Divgi D. R.,M cDermott K.,G riffin T. W. et al.: "Lesion-by-lesion comparison of computerized tomography and indium-I I I-labeled monoclonal antibody CllO radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial". J. Nucl. Med., 1993, 34, 1656.

[27] Fand I., Sharkey R. M., Grundy J. P., Goldenberg D. M.: "Locahzation by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model". Nucl. Med. Biol., 1992, 19, 87.

[28] Schneebaum S.,T roitsaA.,A vital S.,H addad R., KashtanH .,Gitstein G. et al.: "Identification of lymph node metastases in recurrent colorectal cancer". Recent Results Cancer Res., 2000, 157, 281.

[29] Kim J. C., Kim W. S., Ryu J. S., Oh S. J., Lee D. H., Koo K. H. et al.: "Applicability of carcinoembryonic antigen-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma". Cancer Res., 2000, 60, 4825.

[30] Martin E. W. Jr., Thurston M. 0.: "Intraoperative radioimmunodetection". Semin. Surg. Oncol., 1998, 15, 205.

[31] Nabi H. A., Doerr R. J., Balu D., Rogan L., Farrell E. L., Evans N. H.: "Gamma Probe assisted ex vivo detection of small lymph node metastases following the administration of Indium-111-labeled monoclonal antibodies to colorectal cancers". J. Nuc/. Med., 1993, 34, 1818.

[32] ArnoldM .W .,Y oung D.M .,H itchcock C. L.、Barbera-Guillem E., Nieroda C.,M artin E. W. Jr.: "Staging of colorectal cancer: biology vs. morphology". Dis. Colon Rectum, 1998, 41, 1482.

[33] ArnoldM . W.,S chneebaum S., Berens A.,M ojzisik C.,H inkle G., Martin E.W.: "Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer". Surgery, 1992, 112, 624.

[34] Levenback C.: "Intraoperative lymphatic mapping and sentinel node identification: gynecologic applications". Recent Results Cancer Res., 2000, 157, 150.

[35] Lantzsch T.,W oltersM .,G rimmJ .,M ende T.,B uchmannJ .,S liutz G.,H oelbl H.: "Sentinel node procedure in lb cervical cancer: a preliminary series". Br. J. Cancer, 2001, 85, 791.